YTHDF2 Inhibitors Reprogram Tumor-Associated Macrophages for Cancer Immunity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current immunotherapy approaches, such as immune checkpoint inhibitors, have limited efficacy due to the immunosuppressive environment created by tumor-associated macrophages (TAMs) in the tumor microenvironment, which suppress anti-tumor immune responses and promote cancer progression.

Innovation Solution

Targeting tumor-associated macrophages (TAMs) with a YTHDF2 inhibitor, such as a phosphorothioated CpG oligodeoxynucleotide, to disrupt the immunosuppressive state and enhance anti-tumor immunity, combined with immune checkpoint inhibitors like PD-1 or PD-L1 inhibitors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If immune checkpoint inhibitors are used to treat cancer, then immune response is enhanced, but tumor-associated macrophages suppress anti-tumor immunity and limit therapy efficacy

Engineering Contradiction:

Improveefficacy of immune checkpoint therapyVSAvoidimmunosuppressive environment created by TAMs

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and targets the specific harmful component (YTHDF2 protein) within the TAMs that is responsible for maintaining the immunosuppressive environment. By using inhibitors that specifically bind to and block YTHDF2 function, the patent removes this key suppressor without eliminating the entire macrophage population, thereby resolving the contradiction between enhancing immune response and dealing with TAM-mediated suppression.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the functional state of TAMs by inhibiting YTHDF2, which alters the expression of immunosuppressive genes and cytokines. This parameter change transforms TAMs from an immunosuppressive state to a state that is more responsive to immune checkpoint inhibitors, thereby improving overall therapy efficacy while addressing the harmful suppressive environment.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If YTHDF2 is inhibited to promote M1 macrophage polarization, then anti-tumor immunity is enhanced, but combination therapy complexity increases

Engineering Contradiction:

Improveanti-tumor immune responseVSAvoidcombination therapy regimen

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges two therapeutic approaches by combining YTHDF2 inhibition with immune checkpoint inhibitors in a single treatment regimen. This combination targets both the suppressive mechanism (YTHDF2 in TAMs) and the immune activation pathway (checkpoint inhibitors), creating a synergistic effect that enhances anti-tumor immunity while managing the complexity through coordinated molecular targeting.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent uses YTHDF2 inhibition as an intermediary mechanism that facilitates the action of immune checkpoint inhibitors. By first blocking YTHDF2, the patent creates a permissive environment that allows checkpoint inhibitors to work more effectively, thereby enhancing the overall anti-tumor response while structuring the combination therapy in a logical sequence.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250228895A1Compounds to inhibit ythdf2, t helper cells lacking expression of ythdf2, and methods to treat cancer

Publication Date: 2025.07.17 CITY OF HOPE

AI summary

A YTHDF2 inhibitor, such as an antibody, a small molecule, an aptamer, a nucleic acid, a protein, or an enzyme, can be used for inhibiting expression of YTHDF2 in tumor-associated macrophages (TAMs) and in methods of treating cancer. T helper 9 cells that do not express a YTHDF2 protein are useful in inducing an immune response and treating cancer.